Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European Urology

Volumn 53, Issue 5, 2008, Pages 941-949

  Studer, Urs E ^a   Collette, Laurence ^b   Whelan, Peter ^c   Albrecht, Walter ^d   Casselman, Jacques ^e   de Reijke, Theo ^f   Knönagel, Hartmut ^g   Loidl, Wolfgang ^h   Isorna, Santiago ⁱ   Sundaram, Subramanian K ^j   Debois, Muriel ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d Rudolfstiftung   (Austria)

^e Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g Limmattalspital ^*  (Switzerland)

^h Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

ⁱ Hospital Nuestra Senora del Pino   (Spain)

^j PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Androgen deprivation; Deferred treatment; Prostate cancer; PSA doubling time; Survival

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER STAGING; HIGH RISK PATIENT; HUMAN; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41149171703     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.12.032     Document Type: Article

References (15)

1. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599-603
2. Studer U.E., Hauri D., Hanselmann S., et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 22 (2004) 4109-4118
3. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
4. Salminen E.K., Portin R.I., Koskinen A., et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 (2004) 7575-7582
5. Byar D.P. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
6. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the medical research council trial. Br J Urol 1997;79:235-46.
7. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation?. Br J Urol 86 (2000) S220
8. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 24 (2006) 1868-1876
9. Harmer M.H. TNM classifications. 3rd ed. (1978), UICC (Union International Contra Cancer), Geneva
10. Kalbfleisch J.D., and Prentice R.L. Statistical analysis of failure time data (1980), Wiley, New York p. 163-78
11. Korn E.L. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5 (1986) 225-260
12. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
13. Stamey T.A., Kaabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 141 (1989) 1076-1083
14. Choo R., DeBoer G., Klotz L., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Rad Oncol Biol Phys 50 (2001) 615-620
15. Stephenson A.J., Aprikian A.G., Souhami L., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59 (2002) 652-656